Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

Publication date: May 24, 2022

“The screening of patients for COLUMBUS-AD focuses on patients with surgically resected high-risk IIB-C BRAF V600E/K-mutant cutaneous melanoma”, said study coordinator assoc. It is estimated that 18% of stage IIB and 25% of stage IIC patients die from melanoma within 10 years from diagnosis. Available at: 2020 MELANOMA SKIN CANCER REPORT | Melanoma UK. What Causes Melanoma Skin Cancer. Van Akkooi, MD PhD, from the Melanoma Institute Australia (MIA) and past chairman of the EORTC Melanoma Group. 2020 Melanoma Skin Cancer Report. Accessed May 2021. International Agency for Research on Cancer.

Concepts Keywords
Biopharma BRAF
Canada Pdf
Cancer Html
France Targeted therapy
Nct05270044 Encorafenib
Binimetinib
Melanoma
MEK inhibitor
Orphan drugs
Cancer treatments
Cancer
Clinical medicine
Medicine
Clinical infrastructure
Manufacturing
Healthcare

Semantics

Type Source Name
disease MESH Skin Cancer
drug DRUGBANK Coenzyme M
disease MESH actinic keratosis
disease MESH lung cancers
disease MESH development
pathway KEGG Colorectal cancer
disease MESH colorectal cancer
drug DRUGBANK Rasagiline
drug DRUGBANK Tropicamide
disease MESH DNA damage
disease MESH community
disease MESH biopsy
disease MESH diagnosis
drug DRUGBANK Nonoxynol-9
disease MESH Cancer
pathway KEGG Melanoma
disease MESH melanoma
disease MESH recurrence
disease MESH metastasis
drug DRUGBANK Binimetinib
drug DRUGBANK Encorafenib

Original Article

Leave a Comment

Your email address will not be published.